Cell Therapy for Parkinson’s Disease

Author:

Shastry Surabhi12,Hu Junkai12,Ying Mingyao23ORCID,Mao Xiaobo1245ORCID

Affiliation:

1. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

2. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

3. Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205, USA

4. Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA

5. Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

Abstract

Parkinson’s Disease (PD) is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons of the substantia nigra pars compacta with a reduction in dopamine concentration in the striatum. It is a substantial loss of dopaminergic neurons that is responsible for the classic triad of PD symptoms, i.e., resting tremor, muscular rigidity, and bradykinesia. Several current therapies for PD may only offer symptomatic relief and do not address the underlying neurodegeneration of PD. The recent developments in cellular reprogramming have enabled the development of previously unachievable cell therapies and patient-specific modeling of PD through Induced Pluripotent Stem Cells (iPSCs). iPSCs possess the inherent capacity for pluripotency, allowing for their directed differentiation into diverse cell lineages, such as dopaminergic neurons, thus offering a promising avenue for addressing the issue of neurodegeneration within the context of PD. This narrative review provides a comprehensive overview of the effects of dopamine on PD patients, illustrates the versatility of iPSCs and their regenerative abilities, and examines the benefits of using iPSC treatment for PD as opposed to current therapeutic measures. In means of providing a treatment approach that reinforces the long-term survival of the transplanted neurons, the review covers three supplementary avenues to reinforce the potential of iPSCs.

Funder

American Parkinson’s Disease Association

Parkinson’s Foundation the Stanley Fahn Junior Faculty Award

Maryland Stem Cell Research Foundation Discovery Award

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference62 articles.

1. Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy;Kieburtz;Mt. Sinai J. Med.,2007

2. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease;Subramaniam;Prog. Neurobiol.,2013

3. Stoker, T.B., and Greenland, J.C. (2018). Parkinson’s Disease: Pathogenesis and Clinical Aspects, Codon Publications.

4. Functional neuroanatomy of the basal ganglia;Lanciego;Cold Spring Harb. Perspect. Med.,2012

5. Parkinson’s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis;DeMaagd;Pharm. Ther.,2015

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3